n/a PMID: Carcinogenesis. 2018 05 3 ;39(5):700-707. PMID: 29546393 Abstract Title: Bufalin inhibits human breast cancer tumorigenesis by inducing cell death through the ROS-mediated RIP1/RIP3/PARP-1 pathways. Abstract: Bufalin, a key active ingredient of the Chinese medicine Chan Su, inhibits breast cancer tumorigenesis in vitro and in vivo. Here, we found that the pan-caspase inhibitor zVAD-fmk …
Continue reading “Bufalin inhibits human breast cancer tumorigenesis.”
PMID: Colloids Surf B Biointerfaces. 2018 Jun 1 ;166:224-234. Epub 2018 Mar 19. PMID: 29602078 Abstract Title: Increasing the anticancer performance of bufalin (BUF) by introducing an endosome-escaping polymer and tumor-targeting peptide in the design of a polymeric prodrug. Abstract: A well-defined multifunctional brush-type polymeric prodrug covalently linked with an anticancer drug (bufalin, BUF), a …
PMID: Oncol Lett. 2018 May ;15(5):6443-6449. Epub 2018 Feb 21. PMID: 29616114 Abstract Title: Bufalin induces DNA damage response under hypoxic condition in myeloma cells. Abstract: Hypoxia serves a crucial role in the development of drug resistance in various cancer cells. Therefore, many attempts targeting hypoxia are underway to overcome the drug resistance mediated by …
Continue reading “Bufalin induces DNA damage response under hypoxic condition in myeloma cells.”
PMID: Int J Oncol. 2018 Jun ;52(6):2051-2060. Epub 2018 Apr 2. PMID: 29620259 Abstract Title: Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling. Abstract: Sorafenib inhibits tumor growth primarily by inhibiting vessel formation, however, its efficacy requires improvement, therefore, the development of strategies which augment …
Continue reading “Synergistic anti-hepatoma effect of bufalin combined with sorafenib.”
PMID: Indian J Hematol Blood Transfus. 2018 Apr ;34(2):268-272. Epub 2017 Sep 30. PMID: 29622868 Abstract Title: Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation. Abstract: This study was purposed to investigate bufalin combined with AKT inhibitor MK2206 on growth inhibition and apoptosis …
PMID: J Endocrinol. 2018 06 ;237(3):255-269. Epub 2018 Apr 10. PMID: 29636364 Abstract Title: Bufalin suppresses endometriosis progression by inducing pyroptosis and apoptosis. Abstract: The steroid receptor coactivator (SRC)-1 isoform/estrogen receptor (ER)-β axis has an essential role in endometriosis progression. In this context, therefore, bufalin was employed as a 'tool compound' to evaluate inhibitors of …
PMID: Biomed Pharmacother. 2018 Jul ;103:204-215. Epub 2018 Apr 24. PMID: 29653366 Abstract Title: Bufalin inhibits glioblastoma growth by promoting proteasomal degradation of the Na/K-ATPaseα1 subunit. Abstract: Chansu is a traditional Chinese medicine that is generally recognized as a specific inhibitor of Na/K-ATPase. Bufalin, an active component of Chansu, is an endogenous steroid hormone with …
PMID: Mol Med Rep. 2018 Jun ;17(6):8101-8110. Epub 2018 Apr 24. PMID: 29693132 Abstract Title: Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins. Abstract: As one of the most recognized and well‑known drugs for hepatocellular carcinoma (HCC), the antitumor effect of sorafenib against HCC remains to be improved. Bufalin has displayed …
PMID: Mol Clin Oncol. 2018 May ;8(5):631-636. Epub 2018 Mar 21. PMID: 29732152 Abstract Title: Molecular mechanisms underlying the antimetastatic activity of bufalin. Abstract: Bufalin is a monomer compound extract from Chansu, which is a traditional Chinese medicine obtained from the skin and parotid venom glands of toads, such as Bufo bufo gargarizans Cantor and …
Continue reading “Molecular mechanisms underlying the antimetastatic activity of bufalin.”
PMID: Oncoimmunology. 2018 ;7(5):e1426434. Epub 2018 Feb 8. PMID: 29721392 Abstract Title: Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy. Abstract: The Toll-like receptor 3 (TLR3) agonists as polyriboinosinic-polyribocytidylic acid (poly (I:C)) have been implicated as potential immunotherapy adjuvant for cancer whereas the exact roles of TLR3 agonists in …
Health Time